Invizyne IPO Update Call
MDB Capital Co-Founder & CEO Chris Marlett, President & Chief Market Strategist Lou Basenese and Chief Legal Officer Mo Hayat provide the latest status on the Invizyne Technologies IPO, filing of an updated registration statement, addition of a Long Term Investor Right (LTIR) and the anticipated closing. September 11, 2024
Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.
Our parent company, MDB Capital Holdings (Nasdaq: MDBH), and our financial professionals have a financial interest in the equity securities (e.g., option, right, warrant, future, long or short position) of Invizyne Technologies. MDB has three financial professionals who are members of the board of directors of Invizyne.
The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at the following location EDGAR Entity Landing Page (sec.gov). A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing [email protected].
Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.
Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.